三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
IGF-1R靶点药物国内竞争格局(仅统计临床进展达到I期及以上)
IGF-1R靶点药物国内竞争格局(仅统计临床进展达到I期及以上)
竞争格局
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:234KB
图片尺寸:2330*984
同报告图片
/
4
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
所属报告:
信达生物-港股公司深度报告:IO+ADC 全球创新领先减重等慢病开花-250427(30页).pdf
打包全文图表
相关数据
国内在研的IGF-1R靶点药物临床进度总结
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
收藏
行业数据
2025-03-14
原图定位
查看详情
IBI311(替妥尤单抗,IGF-1R)RESTORE-1三期研究结果
5aW955qE77yM5Lul5LiL5piv5oKo5o+Q5L6b55qE5Zu+54mH5YaF5a6555qE5pWw5o2u6KGo5qC85ZKM6LWE5paZ5p2l5rqQ77yaCgp8IOaXtumXtO+8iOWRqO+8iSB8IElCSTMxMe+8iCXvvIkgfCDlronmhbDliYLvvIgl77yJIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwKfCAwICAgICAgICAgIHwgMjcuOCAgICAgICAgIHwgNy4xICAgICAgICAgIHwKfCA2ICAgICAgICAgIHwgNDguMSAgICAgICAgIHwgMTAuNyAgICAgICAgIHwKfCAxMiAgICAgICAgIHwgNzAuNCAgICAgICAgIHwgMTEuMyAgICAgICAgIHwKfCAxOCAgICAgICAgIHwgODUuOCAgICAgICAgIHwgMy44ICAgICAgICAgIHwKfCAyNCAgICAgICAgIHwgODEuOSAgICAgICAgIHwgLSAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muS/oei+vueUn+eJqTIwMjTlubQz5pyI5oqV6LWE6ICF5ryU56S677yM55Sz5LiH5a6P5rqQ56CU56m2
收藏
行业数据
2025-03-14
原图定位
查看详情
IBI311(替妥尤单抗,IGF-1R)作用机理
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
收藏
行业数据
2025-03-14
原图定位
查看详情
IGF-1R靶点药物国内竞争格局(I期及以上)
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
收藏
竞争格局
2024-10-21
原图定位
查看详情
SY707除ALK外针对靶点IGF1R、PTK2B、FAK更差异化
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
收藏
行业数据
2023-05-19
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
甲状腺眼病患者群体广泛,存在巨大未满足临床需求。甲状腺眼病(Thyroid eye disease,TED),是全球最常见的眼眶疾病之一,通常与毒性弥漫性甲状腺肿(Graves 病)相关,约 25%至 50%的 Graves 病患者会出现 TED。作为一种累及眼部组织的自身免疫性疾病,TED 年发病率预估为 16/100,000 人(女性)和 2.9/100,000 人(男性),患病率为 0.1-0.3%。主要表现为眼后组织的炎症和扩张,导致眼球突出(突眼),可能会导致眼睑无法完全闭合,出现复视(双重视力),甚至视网膜神经受压,严重时可导致失明。甲状腺眼病患者在中国目前可用的治疗药物非常有限,60 年无有效新药上市,且已有治疗的效果往往不尽如人意。目前仅极少数发达国家有相关靶向药获批上市,治疗费用高昂,存在巨大的未被满足的临床需求。从发病机制来看,胰岛素样生长因子 1 受体(IGF-1R)起到关键的致病作用。IGF-1R 表达在甲状腺眼病患者的眼眶成纤维细胞、B 细胞和 T 细胞,并和促甲状腺激素受体(TSHR)形成 IGF-1R/TSHR 后通路串扰。如果激活这个通路,会刺激成纤维细胞活化,进而增殖分化成肌成纤维细胞和脂肪细胞,导致组织重塑。
竞争格局
原图定位
当前图表所属:
信达生物-港股公司深度报告:IO+ADC 全球创新领先减重等慢病开花-250427(30页).pdf
IL-23靶点药物国内竞争格局(I期及以上)
玛仕度肽、司美格鲁肽及替尔泊肽不同剂量下减重数据对比(非头对头)
玛仕度肽共有7项III期注册研究进行中
CLDN18.2/CD3双靶点药物研发格局(申报临床及以上)
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》